Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study.

Abstract:

BACKGROUND:Black-white disparities in breast cancer incidence rates and birth outcomes raise concerns about potential disparities in the reproductive health of premenopausal breast cancer survivors. We examined the prevalence of preterm birth (PTB), low birthweight (LBW), and small for gestational age (SGA) by breast cancer history and effect modification by race. METHODS:We analyzed linked North Carolina birth records and Central Cancer Registry files from 1990 to 2009 (n = 2,325,229). We used multivariable negative log-binomial regression to calculate prevalence ratios (PRs) and 95% confidence intervals (CIs) for the association between breast cancer history and PTB, LBW, and SGA. RESULTS:Of 1,912,269 eligible births, 512 births were to mothers with a previous breast cancer diagnosis history. Average age at breast cancer diagnosis was 31.8 years (SD = 4.7). Mean time from diagnosis to delivery was 3.3 years (SD = 2.8). After multivariable adjustment, the PR was 1.67 (95% CI, 1.42-1.97) for PTB, 1.50 (95% CI, 1.23-1.84) for LBW, and 1.30 (95% CI, 1.05-1.61) for SGA comparing women with a breast cancer history to the general population. Among black mothers, the PRs associated with breast cancer history for PTB, LBW, and SGA were 1.31 (95% CI, 1.00-1.72), 1.49 (95% CI, 1.14-1.94), and 1.44 (95% CI, 1.11-1.87), respectively. The corresponding PRs among white mothers were 2.06 (95% CI, 1.67-2.54), 1.53 (95% CI, 1.12-2.08), and 1.10 (95% CI, 0.77-1.58), respectively. The interaction between breast cancer history and race was statistically significant for associations with PTB, but not for LBW or SGA. CONCLUSIONS:In our data, women with a breast cancer history were at higher risk of delivering a PTB, LBW, or SGA infant, especially if they received chemotherapy or gave birth within 2 years of their breast cancer diagnosis date.

journal_name

Breast Cancer Res

authors

Black KZ,Nichols HB,Eng E,Rowley DL

doi

10.1186/s13058-017-0803-z

subject

Has Abstract

pub_date

2017-01-31 00:00:00

pages

11

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-017-0803-z

journal_volume

19

pub_type

杂志文章
  • Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

    abstract:INTRODUCTION:Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2888

    authors: Fuentes G,Scaltriti M,Baselga J,Verma CS

    更新日期:2011-05-22 00:00:00

  • Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study.

    abstract:INTRODUCTION:Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in breast cancer development, but the results of epidemiological studies have been inconsistent. METHODS:We conducted a case-control study nested within two prospective cohorts, the New York University Women's H...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3390

    authors: Scarmo S,Afanasyeva Y,Lenner P,Koenig KL,Horst RL,Clendenen TV,Arslan AA,Chen Y,Hallmans G,Lundin E,Rinaldi S,Toniolo P,Shore RE,Zeleniuch-Jacquotte A

    更新日期:2013-02-26 00:00:00

  • Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

    abstract::Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in cancers include the cancer susceptibility genes p53 and BRCA1. Because mutational inactivation of gene function is specific to tumor ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr26

    authors: Obermiller PS,Tait DL,Holt JT

    更新日期:2000-01-01 00:00:00

  • High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.

    abstract::It is generally accepted that early detection of breast cancer has great impact on patient survival, emphasizing the importance of early diagnosis. In a widely recognized model of breast cancer development, tumor cells progress through chronological and well defined stages. However, the molecular basis of disease prog...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1528

    authors: Rennstam K,Hedenfalk I

    更新日期:2006-01-01 00:00:00

  • Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles.

    abstract:INTRODUCTION:The presence of tumor cells in the axillary lymph nodes is the most important prognostic factor in early stage breast cancer. However, the optimal method for sentinel lymph node (SLN) examination is still sought and currently many different protocols are employed. To examine two approaches for tumor cell d...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2922

    authors: Tveito S,Andersen K,Kåresen R,Fodstad Ø

    更新日期:2011-08-04 00:00:00

  • FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

    abstract:BACKGROUND:Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adh...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01298-3

    authors: Paul R,Luo M,Mo X,Lu J,Yeo SK,Guan JL

    更新日期:2020-06-03 00:00:00

  • ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.

    abstract:INTRODUCTION:Estrogen receptor-α (ER) and human epidermal growth factor receptor 2 (HER2) positivity are inversely correlated by standard criteria. However, we investigated the quantitative relation between ER and HER2 expression at both RNA and protein levels in HER2+ve and HER2-ve breast carcinomas. METHODS:ER and H...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/bcr3145

    authors: Pinhel I,Hills M,Drury S,Salter J,Sumo G,A'Hern R,Bliss JM,Sestak I,Cuzick J,Barrett-Lee P,Harris A,Dowsett M,NCRI Adjuvant Breast Cancer Trial Management Group.

    更新日期:2012-03-14 00:00:00

  • Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression.

    abstract:INTRODUCTION:Mammary stem cells are bipotential and suggested to be the origin of breast cancer development, but are elusive and vaguely characterized. Breast tumors can be divided into subgroups, each one requiring specific treatment. To determine a possible association between mammary stem cells and breast cancer, a ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2256

    authors: Williams C,Helguero L,Edvardsson K,Haldosén LA,Gustafsson JA

    更新日期:2009-01-01 00:00:00

  • Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage.

    abstract::Estrogen-mediated proliferation is fundamental to normal mammary gland development. Recent studies have demonstrated that amphiregulin is a critical paracrine regulator of estrogen action during ductal morphogenesis. These studies implicate a critical role for amphiregulin in mammary stem cell differentiation as well ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1740

    authors: LaMarca HL,Rosen JM

    更新日期:2007-01-01 00:00:00

  • Whither high-dose chemotherapy in breast cancer?

    abstract::Four trials of high-dose chemotherapy with stem cell support in breast cancer in the adjuvant and metastatic settings have shown no long-term disease-free or overall survival gain. This relative failure of a single high-dose therapy we believe opens up the development of a dose-dense approach with block scheduling as ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr262

    authors: Mayer A,Earl H

    更新日期:2001-01-01 00:00:00

  • The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

    abstract:INTRODUCTION:Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1503

    authors: Têtu B,Brisson J,Wang CS,Lapointe H,Beaudry G,Blanchette C,Trudel D

    更新日期:2006-01-01 00:00:00

  • Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

    abstract:INTRODUCTION:Breast cancer subtyping and prognosis have been studied extensively by gene expression profiling, resulting in disparate signatures with little overlap in their constituent genes. Although a previous study demonstrated a prognostic concordance among gene expression signatures, it was limited to only one da...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,meta分析

    doi:10.1186/bcr2124

    authors: Wirapati P,Sotiriou C,Kunkel S,Farmer P,Pradervand S,Haibe-Kains B,Desmedt C,Ignatiadis M,Sengstag T,Schütz F,Goldstein DR,Piccart M,Delorenzi M

    更新日期:2008-01-01 00:00:00

  • PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.

    abstract:INTRODUCTION:Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase that is highly expressed in Human Epidermal Growth Factor 2(+) (Her2(+)) breast cancers. Overexpression of PTK6 enhances anchorage-independent survival, proliferation, and migration of breast cancer cells. We hypothesized that PTK6 inhibiti...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0594-z

    authors: Park SH,Ito K,Olcott W,Katsyv I,Halstead-Nussloch G,Irie HY

    更新日期:2015-06-19 00:00:00

  • Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.

    abstract:BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedb...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01262-1

    authors: Tank A,Peterson HM,Pera V,Tabassum S,Leproux A,O'Sullivan T,Jones E,Cabral H,Ko N,Mehta RS,Tromberg BJ,Roblyer D

    更新日期:2020-03-13 00:00:00

  • 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.

    abstract:INTRODUCTION:17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than shrinkage, making detection of response a challenge. Magnetic resonance spectroscopy (MRS)...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2729

    authors: Brandes AH,Ward CS,Ronen SM

    更新日期:2010-01-01 00:00:00

  • Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.

    abstract:INTRODUCTION:We present a fully automated method for deriving quantitative measures of background parenchymal enhancement (BPE) from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and perform a preliminary evaluation of these measures to assess the effect of risk-reducing salpingo-oophorectomy (R...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0577-0

    authors: Wu S,Weinstein SP,DeLeo MJ 3rd,Conant EF,Chen J,Domchek SM,Kontos D

    更新日期:2015-05-19 00:00:00

  • Breast cancer prognosis by combinatorial analysis of gene expression data.

    abstract:INTRODUCTION:The potential of applying data analysis tools to microarray data for diagnosis and prognosis is illustrated on the recent breast cancer dataset of van 't Veer and coworkers. We re-examine that dataset using the novel technique of logical analysis of data (LAD), with the double objective of discovering patt...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1512

    authors: Alexe G,Alexe S,Axelrod DE,Bonates TO,Lozina II,Reiss M,Hammer PL

    更新日期:2006-01-01 00:00:00

  • Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis.

    abstract:INTRODUCTION:Aberrant microenvironment and endoplasmic reticulum (ER) stress are associated with solid-tumor progression. Stress proteins, like heat shock proteins and glucose-regulated proteins, are frequently overexpressed in human tumors. It has been reported that derlin-1 is involved in ER stress response. In vitro...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1849

    authors: Wang J,Hua H,Ran Y,Zhang H,Liu W,Yang Z,Jiang Y

    更新日期:2008-01-01 00:00:00

  • Can the breast screening appointment be used to provide risk assessment and prevention advice?

    abstract::Breast cancer risk is continuing to increase across all societies with rates in countries with traditionally lower risks catching up with the higher rates in the Western world. Although cure rates from breast cancer have continued to improve such that absolute numbers of breast cancer deaths have dropped in many count...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0595-y

    authors: Evans DG,Howell A

    更新日期:2015-07-09 00:00:00

  • Breast cancer stem cells: implications for therapy of breast cancer.

    abstract::The concept of cancer stem cells responsible for tumour origin, maintenance, and resistance to treatment has gained prominence in the field of breast cancer research. The therapeutic targeting of these cells has the potential to eliminate residual disease and may become an important component of a multimodality treatm...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2111

    authors: Morrison BJ,Schmidt CW,Lakhani SR,Reynolds BA,Lopez JA

    更新日期:2008-01-01 00:00:00

  • Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165].

    abstract:INTRODUCTION:Isoflavones are hypothesized to protect against breast cancer, but it is not clear whether they act as oestrogens or anti-oestrogens in breast tissue. Our aim was to determine the effects of taking a red clover-derived isoflavone supplement daily for 1 year on mammographic breast density. Effects on oestra...

    journal_title:Breast cancer research : BCR

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1186/bcr773

    authors: Atkinson C,Warren RM,Sala E,Dowsett M,Dunning AM,Healey CS,Runswick S,Day NE,Bingham SA

    更新日期:2004-01-01 00:00:00

  • Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age.

    abstract:BACKGROUND:The underlying biological mechanisms through which epidemiologically defined breast cancer risk factors contribute to disease risk remain poorly understood. Identification of the molecular changes associated with cancer risk factors in normal tissues may aid in determining the earliest events of carcinogenes...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0873-y

    authors: Johnson KC,Houseman EA,King JE,Christensen BC

    更新日期:2017-07-10 00:00:00

  • Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

    abstract:INTRODUCTION:Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis. Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2903

    authors: Kodera Y,Katanasaka Y,Kitamura Y,Tsuda H,Nishio K,Tamura T,Koizumi F

    更新日期:2011-06-21 00:00:00

  • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    abstract:INTRODUCTION:The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intrac...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1843

    authors: Sassen A,Rochon J,Wild P,Hartmann A,Hofstaedter F,Schwarz S,Brockhoff G

    更新日期:2008-01-01 00:00:00

  • Breast cancer in Marin County.

    abstract::Two articles previously published in Breast Cancer Research illustrate the high rates of breast cancer in Marin County, a wealthy, urban county immediately northwest of the city of San Francisco. I herein comment on these articles, and on the political/psychological/scientific dilemma presented by regions with high ca...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章,评审

    doi:10.1186/bcr633

    authors: Whittemore AS

    更新日期:2003-01-01 00:00:00

  • Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.

    abstract:INTRODUCTION:BRCA1 and BRCA2 mutation carriers are at increased risk for developing both breast and ovarian cancer. It has been suggested that carriers of BRCA1/2 mutations may also be at increased risk of having recurrent (three or more) miscarriages. Several reproductive factors have been shown to influence the risk ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/bcr1387

    authors: Friedman E,Kotsopoulos J,Lubinski J,Lynch HT,Ghadirian P,Neuhausen SL,Isaacs C,Weber B,Foulkes WD,Moller P,Rosen B,Kim-Sing C,Gershoni-Baruch R,Ainsworth P,Daly M,Tung N,Eisen A,Olopade OI,Karlan B,Saal HM,Garber

    更新日期:2006-01-01 00:00:00

  • The clinical and functional significance of c-Met in breast cancer: a review.

    abstract::c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0547-6

    authors: Ho-Yen CM,Jones JL,Kermorgant S

    更新日期:2015-04-08 00:00:00

  • Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research.

    abstract::The potential for a reduction in dietary fat or for an increase in dietary fiber to reduce breast cancer risk has been debated for some years. It is argued here that available research data, even though extensive, leave open hypotheses ranging from little or no potential to major public health potential for breast can...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr68

    authors: Prentice RL

    更新日期:2000-01-01 00:00:00

  • High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.

    abstract:INTRODUCTION:Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. In breast carcinoma, FAK overexpression has been linked to cancer progression but the prognostic relevance remains unknown. In particular, with regard to lymph node-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr977

    authors: Schmitz KJ,Grabellus F,Callies R,Otterbach F,Wohlschlaeger J,Levkau B,Kimmig R,Schmid KW,Baba HA

    更新日期:2005-01-01 00:00:00

  • Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib

    abstract:INTRODUCTION:Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer resistance to chemotherapeutic agents. We studied the prognostic and predictive value of PIK3CA mutations a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0405-y

    authors: Xu B,Guan Z,Shen Z,Tong Z,Jiang Z,Yang J,DeSilvio M,Russo M,Leigh M,Ellis C

    更新日期:2014-07-24 00:00:00